HİPERTANSIYON TEDAVİ YÖNETİMİNDE ECZACININ ROLÜ: AİLE SAĞLIĞI MERKEZİ’NDE BİR MODEL UYGULAMASI

Amaç: Farmasötik bakım uygulamalarında eczacılar önemli rol oynamaktadır. Bu çalışmada Aile Sağlığı Merkezi’nde bulunan diğer sağlık personellerinin yanı sıra eczacı varlığının potansiyel yararları incelenmiştir.

THE ROLE OF THE PHARMACIST IN HYPERTENSION MANAGEMENT: A MODEL APPLICATION IN PRIMARY HEALTH CARE

Objective: Pharmacists have important roles in pharmaceutical care practices. In this study, it was aimed to investigate the potential benefits of the presence of a pharmacist in PHCs (Primary Health Care) in addition to other health care specialists in Ankara Kecioren Karargahtepe PHC and Ankara Ayas PHC.Material and Method: This study is a quasi-experimental type of study which includes a pre-test and a post-test. Pre-test was given to patients by two pharmacists, which was followed by a basic education on hypertension and its treatment. A post-test was done three months after the pre-test in order to assess the efficiency of the education.Result and Discussion: In total, 103 patients (70.9% female; mean age: 62.84 ± 10.44 years) were analysed before and after receiving counselling from two pharmacists. The results of pre- and post-tests were analyzed by Wilcoxon t-test using SPSS 23.0. As a result of the statistical analysis, the education provided by the pharmacists enhanced the mean patient scores significantly (T0 (pre-test) = 6 (5-7), T1 (post-test) = 8 (6-9); P ˂ 0.05). This study revealed the active role and the requirement of the presence of a pharmacist in addition to other health care providers in PHCs.

___

  • 1. Türk Eczacıları Birliği. Türkiye'de Aile Hekimliği Uygulamasına Genel Bakış: Türk Eczacıları Birliği Raporu. In: Türkiye’de Aile Hekimliği Uygulamaları ve Serbest Eczacılara Yansımaları 2009. Retrieved June 18, 2018, from http://ekutuphane.teb.org.tr/arsiv.php?anabelge_no=398.
  • 2. Van Mil, J.W., Fernandez-Llimos, F. (2013). What is 'pharmaceutical care' in 2013? Pharm Pract (Granada), 11(1), 1–2.
  • 3. Conference of Experts on the Rational Use of Drugs (1985: Nairobi). (1987). The rational use of drugs: report of the Conference of Experts, Nairobi, 25-29 November 1985. World Health Organization, Retrieved June 18, 2018, from https://apps.who.int/iris/handle/10665/37174.
  • 4. Toklu, H.Z., Dülger, G. (2010). Eczacılar için akılcı ilaç kullanımı eğitimi. Sentez, 6, 16-17.
  • 5. Cazarim, MdS., Freitas, Od., Penaforte, T.R., Achcar, A., Pereira, LRL. (2016). Impact assessment of pharmaceutical care in the management of hypertension and coronary risk factors after discharge. PLoS One, 11(6), e0155204.
  • 6. Kearney, PM., Whelton, M., Reynold, K., Muntner P, Whelton PK, He J. (2005). Global burden of hypertension: analysis of worldwide data. Lancet, 365(9455), 217-223.
  • 7. World Health Organization, 2003. Adherence to long-term therapies: evidence for action / [edited by Eduardo Sabaté]. Retrieved June 18, 2018, from http://www.who.int/iris/handle/10665/42682.
  • 8. Fulton, M.M., Allen, E.R. (2005). Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract., 17(4), 123–132.
  • 9. Finkers, F., Maring, J.G., Boersma, F., Taxis, K. (2007). A study of medication reviews to identify drug-related problems of polypharmacy patients in the Dutch nursing home setting. J Clin Pharm Ther., 32(5), 469–476.
  • 10. Morgado, M., Rolo, S., Castelo-Branco, M. (2011). Pharmacist intervention program to enhance hypertension control: a randomised controlled trial. Int J Clin Pharm., 33(1), 132-140.
  • 11. Omboni, S., Sala, E. (2015). The pharmacist and the management of arterial hypertension: the role of blood pressure monitoring and telemonitoring. Expert Rev Cardiovasc Ther., 13(2), 209-221.
  • 12. Green, B.B., Cook, A.J., Ralston, J.D., Fishman, P.A., Catz, S.L., Carlson, J., Carrell, D., Tyll, L., Larson, E.B., Thompson, R.S. (2008). Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. JAMA, 299(24), 2857–2867.
  • 13. Bogden, P.E., Abbott, R.D., Williamson, P., Onopa, J.K., Koontz, L.M. (1998). Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med, 13(11), 740–745.
  • 14. Carter, B.L, Rogers, M., Daly, J., Zheng, S., James, P.A. (2009). The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med., 169(19), 1748–1755.
  • 15. Tachjian, A., Maria, V., Jahangir, A. (2010). Use of herbal products and potential interactions in patients with cardiovascular disease. J Am Coll Cardiol., 55(6), 515–525.
  • 16. American Society of Health System Pharmacists. (1993). ASHP statement on pharmaceutical care. Am J Hosp Pharm., 50, 1720-3.
  • 17. Molokhia, M., Majeed, A. (2017). Current and future perspectives on the management of polypharmacy. BMC Fam Pract., 18, 70.
  • 18. Slight, S.P., Howard, R., Ghaleb, M., Barber, N., Franklin, B.D., Avery, A.J. (2013). The causes of prescribing errors in English general practices: a qualitative study. Br J Gen Pract., 63(615), e713– 20.
  • 19. Komwong, D., Greenfield, G., Zaman, H., Majeed, A., Hayhoe, B. (2018). Clinical pharmacists in primary care: a safe solution to the workforce crisis? J R Soc Med., 111(4), 120-124.
  • 20. Incirkus, K., Nahcivan, N.O. (2011). Kronik hastalık bakımını değerlendirme ölçeği-hasta formu’nun Türkçe versiyonunun geçerlik ve güvenirliği. Dokuz Eylül Üniversitesi Hemşirelik Yüksekokulu Elektronik Dergisi, 4(1), 102-109.
  • 21. Adepu, R., Nagavi, B.G. (2006). General practitioners perceptions about the extended roles of the community pharmacists in the state of Karnataka: a study. Indian J Pharm Sci., 68, 36-40.
  • 22. Kara, B., Uzun, S., Yokusoglu, M., Uzun, M. (2009). Hipertansiyon hastalarında ilaç bilgisinin kan basıncını düşürmek için uygulanan yöntemlere etkisi. TAF Preventive Medicine Bulletin, 8(3), 231-238.
  • 23. Centers for Disease Control and Prevention. CDC 24/7: Saving Lives, Protecting People. Retrieved May 30, 2020, from https://www.cdc.gov/bloodpressure/measure.htm.
  • 24. Tachjian, A., Maria, V., Jahangir, A. (2010). Use of Herbal Products and Potential Interactions in Patients with Cardiovascular Diseases. J Am Coll Cardiol., 55(6), 515–525.
  • 25. O'Shaughnessy, K.M. (2006). Role of diet in hypertension management. Curr Hypertens Rep., 8(4), 292-297.
  • 26. Bazzano, L.A, Green, T., Harrison, T.N., Reynolds, K. (2013). Dietary approaches to prevent hypertension. Curr Hypertens Rep., 15(6), 694–702.
  • 27. Challa, H.J, Uppaluri, K.R. DASH diet (Dietary approaches to stop hypertension). StatPearls. Retrieved May 30, 2020, from https://www.ncbi.nlm.nih.gov/books/NBK482514/.
  • 28. Malet-Larrea, A., Cardenas, V.G, Benito, L.S, Benrimoj, S.I, Calvo, B., Goyenechea, E. (2016). Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review. Expert Rev Pharmacoecon Outcomes Res., 0(ja), null.
  • 29. Polgreen, L.A, Han, J., Carter, B.L., Ardery, G.P., Coffey, C.S., Chrischilles, E.A., James, P.A. (2015). CostEffectiveness of a Physician–Pharmacist Collaboration Intervention to Improve Blood Pressure ControlNovelty and Significance. Hypertension., 66(6), 1145–1151.
  • 30. Santschi, V., Chiolero, A., Colosimo, A.L., Platt, R.W., Taffe, P., Burnier, M., Burnand, B., Paradis, G. (2014). Improving Blood Pressure Control Through Pharmacist Interventions: A Meta Analysis of Randomized Controlled Trials. J Am Heart Assoc Cardiovasc Cerebrovasc Dis., 3(2), e000718.
  • 31. Machado, M., Bajcar, J., Guzzo, G.C., Einarson, T.R. (2007). Sensivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother, 41, 1770-81.
Ankara Üniversitesi Eczacılık Fakültesi Dergisi-Cover
  • ISSN: 1015-3918
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2016
  • Yayıncı: Ankara Üniversitesi Eczacılık Fakültesi
Sayıdaki Diğer Makaleler

MİKROBİYOTANIN HASTALIKLAR ÜZERİNDEKİ ETKİSİ

Betül ÇAKMAK, Bahar İNKAYA

HİPERTANSIYON TEDAVİ YÖNETİMİNDE ECZACININ ROLÜ: AİLE SAĞLIĞI MERKEZİ’NDE BİR MODEL UYGULAMASI

Aysel PEHLİVANLI, Büşra AKYOL, Özlem DEMİREL, Ömer GÖÇÜN, Arzu ONAY BEŞİKÇİ, Arif Tanju ÖZÇELİKAY, Gülbin ÖZÇELİKAY

JASMINUM SAMBAC'IN ANTİ-PEPTİK ÜLSER AKTİVİTE TARAMASI

Thenmozhi M, Rajeswari SİVARAJ

ALTIN NANOPARTİKÜLLER VE KANSERDE KULLANIMLARI

Hatice DEMİRTAŞ, Ceyda ŞENGEL TÜRK

ALT ÜNİTE BAZLI AŞILARIN PULMONER UYGULAMASINA GENEL BAKIŞ

Melike ONGUN, Başaran MUTLU-AĞARDAN, Fusun ACARTURK

ECZACILIK ÖĞRENCİLERİNİN İNTERNET ÖZ-YETERLİKLERİ

Nilay TARHAN

TÜRKİYE’DE DOĞAL OLARAK YETİŞEN BAZI COTONEASTER MEDIK. (ROSACEAE) TÜRLERİNİN KARŞILAŞTIRMALI MORFOLOJİK ÖZELLİKLERİ

Muhammed Mesud HÜRKUL, Ayşegül KÖROĞLU

KRONİK OBSTRÜKTİF AKCİĞER HASTALIĞINDA GLUTATYON-S-TRANSFERAZ MU1 VE TETA1 POLİMORFİZMLERİNİN ROLÜ

Buket HAYAT, Muhsin Selçuk YAVUZ, Mustafa Engin ŞAHİN, Onur DİRİCAN, Sezen YILMAZ, Can YILMAZ, Işıl YILDIRIM, Tülay ÇOBAN, Gülçin GÜLER ŞİMŞEK, Serpil OĞUZTÜZÜN

KRONİK OBSTRÜKTİF AKCİĞER HASTALIĞINDA GLUTATYON-S TRANSFERAZ MU1 VE TETA1 POLİMORFİZMLERİNİN ROLÜ

Buket HAYAT, Muhsin Selçuk YAVUZ, Engin ŞAHİN, Onur DİRİCAN, Sezen YILMAZ SARIALTIN, Can YILMAZ, Işıl YILDIRIM, Tülay ÇOBAN, Gülçin GÜLER ŞİMŞEK, Serpil OĞUZTÜZÜN

NANOTERANOSTİKLER

Meliha EKİNCİ, Derya İLEM-ÖZDEMİR